Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

“The impact of Wegovy on the obesity market has been huge. key opinion leaders (KOLs) interviewed by GlobalData defined it as ‘revolutionary’. Now with Zepbound, the revolution continues ...

CVS’s decision directly threatens a sizable portion of Zepbound’s addressable market. The potential impact of CVS's formulary decision regarding Zepbound may be somewhat limited. Lilly ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... chiefly that it was not a blinded analysis and participants knew which medication they ...

Notably, both Zepbound ... treatment market, and these dips should be viewed as opportunities to enter the stock. Concerns about CVS dropping Zepbound seem overblown, with the impact expected ...

People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from ...